ERBB2 and breast cancer: However, since there are currently no reported data regarding radiation omission in stage I, HER2+ BC after lumpectomy and given the high risk of LRR in HER2+ BC in the absence of anti-HER2 based systemic therapy, we must consider alternative hypotheses for the observed differences in OS in this study.